ReviewDialogues in clinical neuroscience2009
Pharmacogenetics of antipsychotic-induced side effects.
Review in Dialogues in clinical neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01844700 (1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain), which is not on this map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Single-Nucleotide Polymorphisms as Biomarkers of Antipsychotic-Induced Akathisia: Systematic Review.Genes · 2023Pooled it
- The genetics of drug-related movement disorders, an umbrella review of meta-analyses.Molecular psychiatry · 2020Pooled it
- Changes in body weight and psychotropic drugs: a systematic synthesis of the literature.PloS one · 2012Pooled it
- DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia.Pharmacogenetics and genomics · 2010Trial
- Predictive Role of Serotonin Receptor (5HTR2A) and Dopamine Receptor (DRD2) gene polymorphisms in risperidone-induced weight gain and hyperprolactinemia in patients with schizophrenia.European journal of clinical pharmacology · 2025Article
- Decellularization of various tissues and organs through chemical methods.Tissue & cell · 2024Review
- Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal.Biomedicines · 2023Review
- The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia.Genes · 2022Article
- Association ofFrontiers in psychiatry · 2021Article
- Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells.PloS one · 2021Article
- Pipamperone Population Pharmacokinetics Related to Effectiveness and Side Effects in Children and Adolescents.Clinical pharmacokinetics · 2020Article
- Proteomic study revealed antipsychotics-induced nuclear protein regulations in B35 cells are similar to the regulations in C6 cells and rat cortex.BMC pharmacology & toxicology · 2018Article
- Genetics of Common Antipsychotic-Induced Adverse Effects.Molecular neuropsychiatry · 2016Review
- Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms.The pharmacogenomics journal · 2016Article
- Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations.SAGE open medicine · 2016Article
- Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.Schizophrenia bulletin · 2015Article
- The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum.Clinical epigenetics · 2014Article
- Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.Molecular psychiatry · 2012Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently available antipsychotic drugs (APDs) carry significant though highly variable, liability to neurologic and metabolic side effects. Pharmacogenetics approaches offer the possibility of identifying patient-specific biomarkers for predicting risk of these side effects. To date, a few single nucleotide polymorphisms (SNPs) in a handful of genes have received convergent support across multiple studies. The primary focus has been on SNPs in dopamine and serotonin receptor genes: persuasive meta-analytic evidence exists for an effect of the dopamine D2 and D3 receptor genes (DRD2 and DRD3) in risk for tardive dyskinesia (TD) and for an effect of variation at the 5-HT2C receptor gene (HTR2C) for liability to APD-induced weight gain. However, effect sizes appear to be modest, and pharmacoeconomic considerations have not been sufficiently studied, thereby limiting clinical applicability at this time. Effects of these genes and others on risk for TD, extrapyramidal side effects, hyperprolactinemia, and weight gain are reviewed in this article.
Indexed as
Identifiers
20135898PMC3181932W53468456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.